Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Amit Sanyal, MD: A Clinician’s Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Jan

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Nutrition Muscle Loss Compromises Survival in Patients With Cervical Cancer Undergoing Chemoradiotherapy

New Report Shows Colorectal Cancer is Now Leading Cancer Death Among Those Under 50

Prostate Cancer: Novel PSMA-Targeted Radioligand Shows Reduced Salivary Gland Uptake in Preclinical Studies

HCC LLM Advice and Treatment Concordance

Medical Societies Caution Misinformation May Drive Underuse of Lung Cancer Screening